Study Stopped
Sponsor decision to cancel TRIAL, not related to safety concern
Effect of Efpeglenatide on Cardiovascular Outcomes
AMPLITUDE-O
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk
3 other identifiers
interventional
4,076
26 countries
344
Brief Summary
Primary Objective: To demonstrate that efpeglenatide 4 and 6 mg was noninferior to placebo on 3-point major adverse cardiac events (MACE) in Type 2 diabetes mellitus (T2DM) participants at high cardiovascular (CV) risk. Secondary Objectives: To demonstrate that efpeglenatide 4 and 6 mg was superior to placebo in T2DM participants with high CV risk on the following parameters:
- 3-point MACE.
- Expanded CV outcome.
- Composite outcome of new or worsening nephropathy. To assess the safety and tolerability of efpeglenatide 4 and 6 mg, both added to standard of care in T2DM participants at high CV risk.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3 type-2-diabetes-mellitus
Started Apr 2018
Longer than P75 for phase_3 type-2-diabetes-mellitus
344 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 5, 2018
CompletedFirst Posted
Study publicly available on registry
April 12, 2018
CompletedStudy Start
First participant enrolled
April 27, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 10, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 10, 2020
CompletedResults Posted
Study results publicly available
October 15, 2021
CompletedOctober 15, 2021
August 1, 2021
2.6 years
April 5, 2018
September 16, 2021
September 16, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Time to First Occurrence of Major Adverse Cardiovascular Events (MACE): Event Rate Per 100 Participant-years for First Occurrence of Major Cardiovascular (CV) Event - Non-Inferiority Analysis
All MACE positively adjudicated by the clinical endpoint committee (CEC) were used in the analysis of the composite outcome of first occurrence to CV death, non-fatal myocardial infarction (MI), and non-fatal stroke. Kaplan-Meier curves of the cumulative event rate by treatment groups were used to depict the first occurrence of MACE over time. The event rate per 100 participant-years (calculated by 100\*number of participants with events/sum of time at risk (days) over all participants/365.25) measured in terms of number of events per 100 participant-years was reported.
From Day 1 until the date of first adjudicated and confirmed occurrence of major CV event (maximum duration: up to 31.5 months)
Secondary Outcomes (3)
Time to First Occurrence of Major Adverse Cardiovascular Events: Event Rate Per 100 Participant-years for First Occurrence of Major Cardiovascular Event - Superiority Analysis
From Day 1 until the date of first adjudicated and confirmed occurrence of major CV event (maximum duration: up to 31.5 months)
Time to First Occurrence of the Expanded Major Adverse Cardiovascular Events Composite Events: Event Rate Per 100 Participant-years for First Occurrence of Expanded Major Cardiovascular Event
From Day 1 until the date of first adjudicated and confirmed occurrence of major CV event (maximum duration: up to 31.5 months)
Time to First Occurrence of Composite Renal Endpoint: Event Rate Per 100 Participant-years for First Occurrence of Composite Renal Endpoint
From Day 1 until the confirmed occurrence of composite renal endpoint (maximum duration: up to 31.5 months)
Study Arms (3)
Placebo
PLACEBO COMPARATORParticipants received placebo (matched to Efpeglenatide) as subcutaneous (SC) injection once weekly up to end of treatment.
Efpeglenatide 4 mg
EXPERIMENTALParticipants received Efpeglenatide as SC injection 2 milligrams (mg) per week for 4 weeks then 4 mg per week up to end of treatment.
Efpeglenatide 6 mg
EXPERIMENTALParticipants received Efpeglenatide as SC injection 2 mg per week for 4 weeks, then 4 mg per week for 4 weeks and then 6 mg per week up to end of treatment.
Interventions
Pharmaceutical form: Solution for injection, Route of administration: SC
Eligibility Criteria
You may qualify if:
- T2DM with glycosylated hemoglobin (HbA1c) greater than (\>) 7 percentage.
- Age 18 years or older who met at least one of the cardiovascular disease criteria or age 50 years (male), 55 years (female) or older with glomerular filtration rate greater than or equal to 25 and less than 60 milliliters per minute and at least had one cardiovascular risk factor.
- Female participants agreed to follow contraceptive guidance.
- Signed written informed consent.
You may not qualify if:
- Clinically relevant history of gastrointestinal disease associated with prolonged nausea and vomiting.
- History of chronic pancreatitis or acute idiopathic pancreatitis or diagnosis of any type of acute pancreatitis within 3 months prior to screening.
- Personal or family history of medullary thyroid cancer.
- Hypertension (with a systolic blood pressure \>180 millimeters of Mercury \[mmHg\] and/or diastolic blood pressure \>100 mmHg).
- Hospitalization for hypertensive emergency within 3 months prior to randomization.
- Planned coronary procedure or surgery after randomization.
- No documented ophthalmologic exam with fundoscopy within 6 months prior to randomization.
- Retinopathy or maculopathy with treatment, either recent (3 months prior to randomization) or planned during the study.
- Treated with any glucagon-like peptide-1 receptor agonist product alone (eg, exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, semaglutide) or in combination within 3 months prior to screening.
- Use of any Dipeptidyl peptidase 4 inhibitor within 3 months prior to screening.
- Antihyperglycemic treatment had not been stable within 3 months prior to screening.
- The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sanofilead
- Hanmi Pharmaceutical Company Limitedcollaborator
Study Sites (353)
Investigational Site Number 8400032
Sheffield, Alabama, 35660, United States
Investigational Site Number 8400014
Gilbert, Arizona, 85295, United States
Investigational Site Number 8400012
Surprise, Arizona, 85374, United States
Investigational Site Number 8400046
Tucson, Arizona, 85745, United States
Investigational Site Number 8400022
Beverly Hills, California, 90211, United States
Investigational Site Number 8400065
Concord, California, 94520, United States
Investigational Site Number 8400060
Greenbrae, California, 94904, United States
Investigational Site Number 8400084
Long Beach, California, 90807, United States
Investigational Site Number 8400002
Los Gatos, California, 95032, United States
Investigational Site Number 8400085
Northridge, California, 91325, United States
Investigational Site Number 8400082
Pomona, California, 91767, United States
Investigational Site Number 8400025
Sacramento, California, 95821, United States
Investigational Site Number 8400064
Englewood, Colorado, 80113, United States
Investigational Site Number 8400019
Hamden, Connecticut, 06517, United States
Investigational Site Number 8400023
Waterbury, Connecticut, 06708-3346, United States
Investigational Site Number 8400091
Hialeah, Florida, 33012, United States
Investigational Site Number 8400040
Hollywood, Florida, 33024, United States
Investigational Site Number 8400073
Hudson, Florida, 34667, United States
Investigational Site Number 8400011
Jacksonville, Florida, 32204, United States
Investigational Site Number 8400017
Jacksonville, Florida, 32204, United States
Investigational Site Number 8400042
Jacksonville, Florida, 32277, United States
Investigational Site Number 8400027
Miami, Florida, 33126, United States
Investigational Site Number 8400051
Miami, Florida, 33136, United States
Investigational Site Number 8400041
New Port Richey, Florida, 34652, United States
Investigational Site Number 8400059
Ormond Beach, Florida, 32174, United States
Investigational Site Number 8400006
Macon, Georgia, 31210-1359, United States
Investigational Site Number 8400008
Roswell, Georgia, 30076, United States
Investigational Site Number 8400081
Idaho Falls, Idaho, 83404, United States
Investigational Site Number 8400095
Arlington Heights, Illinois, 60005, United States
Investigational Site Number 8400070
Chicago, Illinois, 60607, United States
Investigational Site Number 8400036
Crystal Lake, Illinois, 60012, United States
Investigational Site Number 8400030
New Albany, Indiana, 46113, United States
Investigational Site Number 8400074
Topeka, Kansas, 66606, United States
Investigational Site Number 8400077
Owensboro, Kentucky, 42303, United States
Investigational Site Number 8400043
Paris, Kentucky, 40361, United States
Investigational Site Number 8400034
Alexandria, Louisiana, 71301, United States
Investigational Site Number 8400079
Monroe, Louisiana, 71203, United States
Investigational Site Number 8400013
New Orleans, Louisiana, 70112, United States
Investigational Site Number 8400047
Oxon Hill, Maryland, 20745, United States
Investigational Site Number 8400001
Flint, Michigan, 48504, United States
Investigational Site Number 8400061
Flint, Michigan, 48532-3447, United States
Investigational Site Number 8400010
Troy, Michigan, 48085, United States
Investigational Site Number 8400005
Troy, Michigan, 48098, United States
Investigational Site Number 8400024
Saint Paul, Minnesota, 55102, United States
Investigational Site Number 8400045
St Louis, Missouri, 63136, United States
Investigational Site Number 8400071
Billings, Montana, 59103, United States
Investigational Site Number 8400028
Great Falls, Montana, 59405-4507, United States
Investigational Site Number 8400086
Kalispell, Montana, 59901, United States
Investigational Site Number 8400037
Las Vegas, Nevada, 89128, United States
Investigational Site Number 8400087
Raritan, New Jersey, 08869, United States
Investigational Site Number 8400056
Staten Island, New York, 10301, United States
Investigational Site Number 8400018
The Bronx, New York, 00000, United States
Investigational Site Number 8400076
Greenville, North Carolina, 27834-5704, United States
Investigational Site Number 8400007
Morehead City, North Carolina, 28557, United States
Investigational Site Number 8400093
Morehead City, North Carolina, 28557, United States
Investigational Site Number 8400094
Morganton, North Carolina, 28655, United States
Investigational Site Number 8400029
Fargo, North Dakota, 58104, United States
Investigational Site Number 8400031
Columbus, Ohio, 43203, United States
Investigational Site Number 8400078
Lorain, Ohio, 44053, United States
Investigational Site Number 8400072
Bend, Oregon, 97702, United States
Investigational Site Number 8400067
Beaver, Pennsylvania, 15009-1957, United States
Investigational Site Number 8400096
Philadelphia, Pennsylvania, 19107, United States
Investigational Site Number 8400021
Pittsburgh, Pennsylvania, 15212, United States
Investigational Site Number 8400015
Greer, South Carolina, 29651, United States
Investigational Site Number 8400063
Murrells Inlet, South Carolina, 29576, United States
Investigational Site Number 8400044
Rapid City, South Dakota, 57702, United States
Investigational Site Number 8400016
Memphis, Tennessee, 38163, United States
Investigational Site Number 8400009
Nashville, Tennessee, 37203, United States
Investigational Site Number 8400055
Corpus Christi, Texas, 78814, United States
Investigational Site Number 8400097
Dallas, Texas, 75230, United States
Investigational Site Number 8400088
El Paso, Texas, 79935, United States
Investigational Site Number 8400058
Fort Worth, Texas, 76132, United States
Investigational Site Number 8400069
Houston, Texas, 77004, United States
Investigational Site Number 8400089
Houston, Texas, 77030, United States
Investigational Site Number 8400092
Richmond, Texas, 77469, United States
Investigational Site Number 8400033
Waco, Texas, 76710, United States
Investigational Site Number 8400039
Salt Lake City, Utah, 84102, United States
Investigational Site Number 8400052
Norfolk, Virginia, 23510, United States
Investigational Site Number 8400049
Manitowoc, Wisconsin, 54220, United States
Investigational Site Number 0320009
Buenos Aires, 1430, Argentina
Investigational Site Number 0320002
Caba, 1120, Argentina
Investigational Site Number 0320013
Caba, 1425DES, Argentina
Investigational Site Number 0320010
Caba, 1425, Argentina
Investigational Site Number 0320005
Caba, C1119ACN, Argentina
Investigational Site Number 0320008
Capital Federal, C1056ABJ, Argentina
Investigational Site Number 0320001
Capital Federal, C1179AAB, Argentina
Investigational Site Number 0320004
Corrientes, W3400AMZ, Argentina
Investigational Site Number 0320012
Corrientes, W3410AVV, Argentina
Investigational Site Number 0320011
Godoy Cruz, M5501ARP, Argentina
Investigational Site Number 0320007
Mar del Plata, B7600FZN, Argentina
Investigational Site Number 0320006
Merlo, B1722COV, Argentina
Investigational Site Number 0320015
Rosario, 2000, Argentina
Investigational Site Number 0320017
Rosario, S2002OJP, Argentina
Investigational Site Number 0320003
Salta, 4400, Argentina
Investigational Site Number 0320018
Salta, 4400, Argentina
Investigational Site Number 0320016
San Isidro, B1642DCB, Argentina
Investigational Site Number 0320014
Santa Rosa, Argentina
Investigational Site Number 1000011
Blagoevgrad, 2700, Bulgaria
Investigational Site Number 1000014
Dimitrovgrad, Bulgaria
Investigational Site Number 1000017
Gabrovo, 5300, Bulgaria
Investigational Site Number 1000007
Kazanlak, 6100, Bulgaria
Investigational Site Number 1000013
Kyustendil, Bulgaria
Investigational Site Number 1000010
Lovech, 5500, Bulgaria
Investigational Site Number 1000008
Plovdiv, 4000, Bulgaria
Investigational Site Number 1000002
Plovdiv, 4002, Bulgaria
Investigational Site Number 1000012
Rousse, 7002, Bulgaria
Investigational Site Number 1000003
Sofia, 1233, Bulgaria
Investigational Site Number 1000001
Sofia, 1431, Bulgaria
Investigational Site Number 1000005
Sofia, 1750, Bulgaria
Investigational Site Number 1000006
Stara Zagora, 6000, Bulgaria
Investigational Site Number 1000009
Varna, 9000, Bulgaria
Investigational Site Number 1000016
Yambol, 8600, Bulgaria
Investigational Site Number 1240001
Barrie, L4N 7L3, Canada
Investigational Site Number 1240002
Brampton, L6S 0C6, Canada
Investigational Site Number 1240018
Burlington, L7M 1K9, Canada
Investigational Site Number 1240021
Burlington, L7R 1E2, Canada
Investigational Site Number 1240007
Calgary, T2H 2G4, Canada
Investigational Site Number 1240020
Calgary, T2V 4J2, Canada
Investigational Site Number 1240024
Chicoutimi, G7H 7K9, Canada
Investigational Site Number 1240004
Concord, L4K 4M2, Canada
Investigational Site Number 1240005
Etobicoke, M9R 4E1, Canada
Investigational Site Number 1240022
Greater Sudbury, P3E 4H5, Canada
Investigational Site Number 1240011
Lévis, G6W 0M5, Canada
Investigational Site Number 1240025
London, N5W 6A2, Canada
Investigational Site Number 1240028
London, N6A 5R8, Canada
Investigational Site Number 1240029
Mirabel, J7J 2K8, Canada
Investigational Site Number 1240008
Montreal, H1M 1B1, Canada
Investigational Site Number 1240031
Montreal, H1T 1C8, Canada
Investigational Site Number 1240014
Montreal, H4A 2C6, Canada
Investigational Site Number 1240023
Montreal, H4A 3T2, Canada
Investigational Site Number 1240017
Montreal, H4N 2W2, Canada
Investigational Site Number 1240015
Oakville, L6M 1M1, Canada
Investigational Site Number 1240012
Oshawa, L1J 2K1, Canada
Investigational Site Number 1240030
Ottawa, K2J 0V2, Canada
Investigational Site Number 1240027
Peterborough, K9J 0B2, Canada
Investigational Site Number 1240016
Pointe-Claire, H9R 4S3, Canada
Investigational Site Number 1240010
Québec, G1N 4V3, Canada
Investigational Site Number 1240019
Red Deer, T4N 6V7, Canada
Investigational Site Number 1240006
Sherbrooke, J1L 0H8, Canada
Investigational Site Number 1240013
Toronto, M4G 3E8, Canada
Investigational Site Number 1240003
Vancouver, V5Y 3W2, Canada
Investigational Site Number 1240026
Victoria, V8V 4A1, Canada
Investigational Site Number 1240009
Victoriaville, G6P 6P6, Canada
Investigational Site Number 1520012
Antofagasta, 1270013, Chile
Investigational Site Number 1520008
Concepción, 4070566, Chile
Investigational Site Number 1520013
Santiago, 7500571, Chile
Investigational Site Number 1520002
Santiago, 7500710, Chile
Investigational Site Number 1520007
Santiago, 7500710, Chile
Investigational Site Number 1520011
Santiago, 7770086, Chile
Investigational Site Number 1520010
Santiago, 8053095, Chile
Investigational Site Number 1520001
Santiago, 8330336, Chile
Investigational Site Number 1520003
Santiago, 8380456, Chile
Investigational Site Number 1520014
Santiago, 8900132, Chile
Investigational Site Number 1520005
Santiago, Chile
Investigational Site Number 1520006
Temuco, 4813299, Chile
Investigational Site Number 1520004
Viña del Mar, Chile
Investigational Site Number 2080004
Aarhus N, 8200, Denmark
Investigational Site Number 2080005
Esbjerg, 6700, Denmark
Investigational Site Number 2080001
Hellerup, 2900, Denmark
Investigational Site Number 2080003
Hvidovre, 2650, Denmark
Investigational Site Number 2080002
København NV, 2400, Denmark
Investigational Site Number 2330002
Pärnu, 80018, Estonia
Investigational Site Number 2330001
Tallinn, 13419, Estonia
Investigational Site Number 2330003
Viljandi, 71024, Estonia
Investigational Site Number 2460002
Helsinki, 00100, Finland
Investigational Site Number 2460001
Jyväskylä, 40620, Finland
Investigational Site Number 2460003
Kuopio, 70100, Finland
Investigational Site Number 2460004
Oulu, 90220, Finland
Investigational Site Number 2760006
Berlin, 10437, Germany
Investigational Site Number 2760009
Berlin, 12627, Germany
Investigational Site Number 2760004
Essen, 45355, Germany
Investigational Site Number 2760008
Frankfurt am Main, 60313, Germany
Investigational Site Number 2760005
Münster, 48145, Germany
Investigational Site Number 2760003
Oldenburg in Holstein, 23758, Germany
Investigational Site Number 2760002
Pirna, 01796, Germany
Investigational Site Number 2760007
Rotenburg an der Fulda, 36199, Germany
Investigational Site Number 3480012
Balatonfüred, 8230, Hungary
Investigational Site Number 3480011
Budapest, 1036, Hungary
Investigational Site Number 3480003
Budapest, 1042, Hungary
Investigational Site Number 3480005
Budapest, 1106, Hungary
Investigational Site Number 3480001
Budapest, 1122, Hungary
Investigational Site Number 3480006
Budapest, 1134, Hungary
Investigational Site Number 3480002
Debrecen, 4032, Hungary
Investigational Site Number 3480009
Komárom, 2900, Hungary
Investigational Site Number 3480008
Mosonmagyaróvár, 9200, Hungary
Investigational Site Number 3480007
Székesfehérvár, 8000, Hungary
Investigational Site Number 3480004
Zalaegerszeg, 8900, Hungary
Investigational Site Number 3560001
Belagavi, 590010, India
Investigational Site Number 3560002
Gūrgaon, 122001, India
Investigational Site Number 3560007
Kolkata, 700073, India
Investigational Site Number 3560006
Lucknow, 226002, India
Investigational Site Number 3560003
New Delhi, 110 029, India
Investigational Site Number 3560009
New Delhi, 110060, India
Investigational Site Number 3560010
Pune, 411001, India
Investigational Site Number 3560005
Pune, 411010, India
Investigational Site Number 3560004
Vellore, 632004, India
Investigational Site Number 3800006
Catania, 95123, Italy
Investigational Site Number 3800003
Catanzaro, 88100, Italy
Investigational Site Number 3800005
Catanzaro, 88100, Italy
Investigational Site Number 3800002
Chieti, 66013, Italy
Investigational Site Number 3800001
Milan, 20132, Italy
Investigational Site Number 3800004
Roma, 00133, Italy
Investigational Site Number 4280004
Daugavpils, LV-5417, Latvia
Investigational Site Number 4280002
Liepāja, LV3414, Latvia
Investigational Site Number 4280001
Riga, LV-1011, Latvia
Investigational Site Number 4280003
Sigulda, LV-2150, Latvia
Investigational Site Number 4400001
Kaunas, 49449, Lithuania
Investigational Site Number 4400002
Kaunas, 50161, Lithuania
Investigational Site Number 4400003
Klaipėda, 92111, Lithuania
Investigational Site Number 4400004
Vilnius, 08661, Lithuania
Investigational Site Number 4840004
Actopan, 42500, Mexico
Investigational Site Number 4840007
Aguascalientes, 20230, Mexico
Investigational Site Number 4840009
Aguascalientes, 20230, Mexico
Investigational Site Number 4840013
Aguascalientes, 20230, Mexico
Investigational Site Number 4840014
Chihuahua City, 31000, Mexico
Investigational Site Number 4840002
Cuernavaca, 62250, Mexico
Investigational Site Number 4840016
Durango, 34000, Mexico
Investigational Site Number 4840015
Durango, 34080, Mexico
Investigational Site Number 4840006
Guadalajara, 44210, Mexico
Investigational Site Number 4840003
Guadalajara, 44600, Mexico
Investigational Site Number 4840005
Guadalajara, 44650, Mexico
Investigational Site Number 4840011
Monterrey, 64020, Mexico
Investigational Site Number 4840010
Monterrey, 64060, Mexico
Investigational Site Number 4840001
Monterrey, 64460, Mexico
Investigational Site Number 5780002
Hamar, 2317, Norway
Investigational Site Number 5780001
Oslo, Norway
Investigational Site Number 5780003
Stavanger, 4011, Norway
Investigational Site Number 6040007
Lima, LIMA 01, Peru
Investigational Site Number 6040004
Lima, LIMA 11, Peru
Investigational Site Number 6040003
Lima, LIMA 27, Peru
Investigational Site Number 6040006
Lima, LIMA 31, Peru
Investigational Site Number 6040001
Lima, Peru
Investigational Site Number 6040005
Lima, Peru
Investigational Site Number 6040002
Piura, 20000, Peru
Investigational Site Number 6160017
Bialystok, 15-404, Poland
Investigational Site Number 6160018
Bydgoszcz, 80-095, Poland
Investigational Site Number 6160015
Bydgoszcz, 85-090, Poland
Investigational Site Number 6160016
Gdansk, 80-546, Poland
Investigational Site Number 6160012
Gdansk, 80-858, Poland
Investigational Site Number 6160005
Katowice, 40-530, Poland
Investigational Site Number 6160006
Płock, 09-402, Poland
Investigational Site Number 6160011
Skierniewice, 96-100, Poland
Investigational Site Number 6160013
Skorzewo, 60-185, Poland
Investigational Site Number 6160010
Szczecin, 70-506, Poland
Investigational Site Number 6160007
Torun, 87-100, Poland
Investigational Site Number 6160009
Torun, 87-100, Poland
Investigational Site Number 6160014
Tychy, 43-100, Poland
Investigational Site Number 6160002
Warsaw, 02-507, Poland
Investigational Site Number 6160004
Wroclaw, 50-315, Poland
Investigational Site Number 6420007
Bacau, 600154, Romania
Investigational Site Number 6420001
Brasov, 500097, Romania
Investigational Site Number 6420011
Brasov, 500365, Romania
Investigational Site Number 6420009
Bucharest, 020475, Romania
Investigational Site Number 6420012
Oradea, 410151, Romania
Investigational Site Number 6420005
Oradea, 410159, Romania
Investigational Site Number 6420010
Oradea, 410169, Romania
Investigational Site Number 6420008
Ploieşti, 100561, Romania
Investigational Site Number 6420002
Târgu Mureş, 540142, Romania
Investigational Site Number 6420003
Târgu Mureş, 540142, Romania
Investigational Site Number 6430018
Kaliningrad, 236035, Russia
Investigational Site Number 6430014
Kazan', 420087, Russia
Investigational Site Number 6430001
Kemerovo, 650002, Russia
Investigational Site Number 6430017
Krasnogorsk, 143408, Russia
Investigational Site Number 6430004
Moscow, 111539, Russia
Investigational Site Number 6430005
Moscow, 117292, Russia
Investigational Site Number 6430002
Moscow, 121374, Russia
Investigational Site Number 6430015
Moscow, 121552, Russia
Investigational Site Number 6430009
Novosibirsk, 630055, Russia
Investigational Site Number 6430019
Novosibirsk, 630087, Russia
Investigational Site Number 6430006
Saint Petersburg, 190013, Russia
Investigational Site Number 6430010
Saint Petersburg, 193312, Russia
Investigational Site Number 6430011
Saint Petersburg, 193312, Russia
Investigational Site Number 6430013
Saint Petersburg, 194156, Russia
Investigational Site Number 6430016
Saint Petersburg, 195067, Russia
Investigational Site Number 6430012
Saint Petersburg, 198205, Russia
Investigational Site Number 6430003
Saratov, 410028, Russia
Investigational Site Number 6430020
Saratov, 410039, Russia
Investigational Site Number 6880001
Belgrade, 11000, Serbia
Investigational Site Number 6880002
Belgrade, 11000, Serbia
Investigational Site Number 6880003
Belgrade, 11050, Serbia
Investigational Site Number 6880005
Belgrade, 11050, Serbia
Investigational Site Number 6880004
Kragujevac, 34000, Serbia
Investigational Site Number 6880006
Novi Sad, 21000, Serbia
Investigational Site Number 7030007
Bratislava, 85101, Slovakia
Investigational Site Number 7030001
Košice, 040 01, Slovakia
Investigational Site Number 7030004
Košice, 040 01, Slovakia
Investigational Site Number 7030003
Kráľovský Chlmec, 077 01, Slovakia
Investigational Site Number 7030009
Moldava nad Bodvou, 04525, Slovakia
Investigational Site Number 7030010
Pezinok, 90201, Slovakia
Investigational Site Number 7030006
Považská Bystrica, 01701, Slovakia
Investigational Site Number 7030005
Prešov, 080 01, Slovakia
Investigational Site Number 7030008
Rožňava, 04801, Slovakia
Investigational Site Number 7030011
Štúrovo, 943 01, Slovakia
Investigational Site Number 7030002
Trebišov, 075 01, Slovakia
Investigational Site Number 7030012
Trenčín, 91101, Slovakia
Investigational Site Number 7100007
Bloemfontein, 9301, South Africa
Investigational Site Number 7100005
Cape Town, 7130, South Africa
Investigational Site Number 7100006
Cape Town, South Africa
Investigational Site Number 7100003
Johannesburg, 1752, South Africa
Investigational Site Number 7100001
Johannesburg, 2198, South Africa
Investigational Site Number 7100002
Parow, 7500, South Africa
Investigational Site Number 7100004
Rivonia, 2128, South Africa
Investigational Site Number 7100008
Umhlanga Rocks Suburb, South Africa
Investigational Site Number 4100006
Guri-si, Gyeonggi-do, 11923, South Korea
Investigational Site Number 4100007
Busan, 49241, South Korea
Investigational Site Number 4100005
Seoul, 02841, South Korea
Investigational Site Number 4100002
Seoul, 03080, South Korea
Investigational Site Number 4100009
Seoul, 03181, South Korea
Investigational Site Number 4100001
Seoul, 03722, South Korea
Investigational Site Number 4100011
Seoul, 06351, South Korea
Investigational Site Number 4100003
Seoul, 06591, South Korea
Investigational Site Number 4100010
Seoul, 08308, South Korea
Investigational Site Number 4100008
Wŏnju, 26426, South Korea
Investigational Site Number 7240008
Alcorcón, 28922, Spain
Investigational Site Number 7240002
Barcelona, 08035, Spain
Investigational Site Number 7240009
Barcelona, 08041, Spain
Investigational Site Number 7240007
Granada, 18014, Spain
Investigational Site Number 7240010
Madrid, 28023, Spain
Investigational Site Number 7240001
Madrid, 28040, Spain
Investigational Site Number 7240006
Majadahonda, 28222, Spain
Investigational Site Number 7240011
Málaga, 29010, Spain
Investigational Site Number 7240005
Olot, 17800, Spain
Investigational Site Number 7240003
San Sebastián de los Reyes, 28702, Spain
Investigational Site Number 7240013
Seville, 41014, Spain
Investigational Site Number 7240004
Valencia, 46010, Spain
Investigational Site Number 7240014
Valencia, 46026, Spain
Investigational Site Number 7520006
Gothenburg, 41345, Sweden
Investigational Site Number 7520003
Helsingborg, 252 20, Sweden
Investigational Site Number 7520004
Kristianstad, 291 85, Sweden
Investigational Site Number 7520002
Malmo, 211 52, Sweden
Investigational Site Number 7520005
Skövde, 541 40, Sweden
Investigational Site Number 7520001
Stockholm, 171 76, Sweden
Investigational Site Number 7920005
Adana, 01250, Turkey (Türkiye)
Investigational Site Number 7920010
Ankara, 06490, Turkey (Türkiye)
Investigational Site Number 7920012
Antalya, 07070, Turkey (Türkiye)
Investigational Site Number 7920015
Aydin, 09100, Turkey (Türkiye)
Investigational Site Number 7920002
Bursa, 16059, Turkey (Türkiye)
Investigational Site Number 7920013
Eskişehir, 26040, Turkey (Türkiye)
Investigational Site Number 7920001
Istanbul, 34393, Turkey (Türkiye)
Investigational Site Number 7920006
Istanbul, 34843, Turkey (Türkiye)
Investigational Site Number 7920011
İzmit, 41380, Turkey (Türkiye)
Investigational Site Number 7920014
Kütahya, 43040, Turkey (Türkiye)
Investigational Site Number 7920007
Samsun, 55139, Turkey (Türkiye)
Investigational Site Number 7920009
Sivas, 58140, Turkey (Türkiye)
Investigational Site Number 8040006
Dnipro, 49005, Ukraine
Investigational Site Number 8040009
Ivano-Frankivsk, 76008, Ukraine
Investigational Site Number 8040001
Ivano-Frankivsk, 76018, Ukraine
Investigational Site Number 8040003
Kharkiv, 61124, Ukraine
Investigational Site Number 8040002
Kharkiv, 61166, Ukraine
Investigational Site Number 8040007
Kiev, 02091, Ukraine
Investigational Site Number 8040008
Kyiv, 01004, Ukraine
Investigational Site Number 8040004
Ternopil, 46000, Ukraine
Investigational Site Number 8040005
Vinnytsia, 21001, Ukraine
Related Publications (5)
Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, Lam CSP, Khurmi NS, Heenan L, Del Prato S, Dyal L, Branch K; AMPLITUDE-O Trial Investigators. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med. 2021 Sep 2;385(10):896-907. doi: 10.1056/NEJMoa2108269. Epub 2021 Jun 28.
PMID: 34215025RESULTNatale P, Green SC, Tunnicliffe DJ, Pellegrino G, Toyama T, Strippoli GF. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.
PMID: 39963952DERIVEDGerstein HC, Li Z, Ramasundarahettige C, Baek S, Branch KRH, Del Prato S, Lam CSP, Lopes RD, Pratley R, Rosenstock J, Sattar N. Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial. Circulation. 2023 Mar 28;147(13):1004-1013. doi: 10.1161/CIRCULATIONAHA.122.063716. Epub 2023 Feb 20.
PMID: 36802715DERIVEDLam CSP, Ramasundarahettige C, Branch KRH, Sattar N, Rosenstock J, Pratley R, Del Prato S, Lopes RD, Niemoeller E, Khurmi NS, Baek S, Gerstein HC. Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation. 2022 Feb 22;145(8):565-574. doi: 10.1161/CIRCULATIONAHA.121.057934. Epub 2021 Nov 14.
PMID: 34775781DERIVEDGerstein HC, Branch K, Heenan L, Del Prato S, Khurmi NS, Lam CSP, Pratley R, Rosenstock J, Sattar N. Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist. Diabetes Obes Metab. 2021 Feb;23(2):318-323. doi: 10.1111/dom.14223. Epub 2020 Oct 22.
PMID: 33026143DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Limitations and Caveats
The study was terminated early by the Sponsor but not due to any safety concerns.
Results Point of Contact
- Title
- Trial Transparency Team
- Organization
- Sanofi
Study Officials
- STUDY DIRECTOR
Clinical Sciences & Operations
Sanofi
Publication Agreements
- PI is Sponsor Employee
- No
- Restriction Type
- OTHER
- Restrictive Agreement
- Yes
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 5, 2018
First Posted
April 12, 2018
Study Start
April 27, 2018
Primary Completion
December 10, 2020
Study Completion
December 10, 2020
Last Updated
October 15, 2021
Results First Posted
October 15, 2021
Record last verified: 2021-08
Data Sharing
- IPD Sharing
- Will not share
No plan to share individual participant data (IPD) by Sanofi: product rights transferred to Hanmi pharmaceutical.